Lalit Pallan

Lalit Pallan

Auto-generated profile, based on publicly available information

Lalit Pallan

University Hospitals Birmingham NHS Foundation Trust , Birmingham, B15 2GW

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2021 in European Journal of Cancer
Verified
Journal Article
Closed access
AHAdriana Hepner
Adriana Hepner
VAVictoria G. Atkinson
Victoria G. Atkinson
JLJames Larkin
James Larkin
RBRebecca A. Burrell
Rebecca A. Burrell
MCMatteo S. Carlino
Matteo S. Carlino
AMAlexander M. Menzies
Alexander M. Menzies

26 May 2022 in European Journal of Cancer
Verified
Journal Article
Open access
Carl-Jacob HolmbergCarl-Jacob Holmberg
Carl-Jacob Holmberg
Lars NyLars Ny
Lars Ny
THTina J. Hieken
Tina J. Hieken
MBMatthew S. Block
Matthew S. Block
MCMichael J. Carr
Michael J. Carr
Roger Olofsson BaggeRoger Olofsson Bagge
Roger Olofsson Bagge
Guidelines addressing melanoma in-transit metastasis (ITM) recommend immune checkpoint inhibitors (ICI) as a first-line treatment option, despite the fact that there are no efficacy data available from prospective trials for exclusively ITM disease. The study aims to analyze the outcome of patients with ITM treated with ICI based on data from a large cohort of patients treated at international referral clinics. A multicenter retrospective cohort study of patients treated between January 2015 and December 2020 from Australia, Europe, and the USA, evaluating treatment with ICI for ITM with or without nodal involvement (AJCC8 N1c, N2c, and N3c) and without distant disease (M0). Treatment was with PD-1 inhibitor (nivolumab or pembrolizumab) and/or CTLA-4 inhibitor (ipilimumab). The response was evaluated according to the RECIST criteria modified for cutaneous lesions. A total of 287 patients from 21 institutions in eight countries were included. Immunotherapy was first-line treatment in 64 (22%) patients. PD-1 or CTLA-4 inhibitor monotherapy was given in 233 (81%) and 23 (8%) patients, respectively, while 31 (11%) received both in combination. The overall response rate was 56%, complete response (CR) rate was 36%, and progressive disease (PD) rate was 32%. Median PFS was ten months (95% CI 7.4-12.6 months) with a one-, two-, and five-year PFS rate of 48%, 33%, and 18%, respectively. Median MSS was not reached, and the one-, two-, and five-year MSS rates were 95%, 83%, and 71%, respectively. Systemic immunotherapy is an effective treatment for melanoma ITM. Future studies should evaluate the role of systemic immunotherapy in the context of multimodality therapy, including locoregional treatments such as surgery, intralesional therapy, and regional therapies.

6 August 2025 in Clinical Medicine
Verified
Journal Article
Open access
BFBenjamin A. Fisher
Benjamin A. Fisher
AAAndrew Allard
Andrew Allard
SDShirish Dubey
Shirish Dubey
KMKulveer Mankia
Kulveer Mankia
APArthur G Pratt
Arthur G Pratt
LPLalit Pallan
Lalit Pallan
Immune checkpoint inhibitors (ICI) used for the treatment of malignancy are associated with immune-related adverse events, which include inflammatory arthritis. ICI-induced inflammatory arthritis (ICI-IA) is a new clinical entity that may lead to functional impairment and may be persistent even after ICI cessation. We discuss the clinical features, investigation and differential diagnosis. Management needs to consider the safety of immunosuppression in the context of the underlying cancer, and current practice will be further informed by ongoing clinical trials.

20 May 2016 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
SESarah Gabrielle Ellis
Sarah Gabrielle Ellis
LPLalit Pallan
Lalit Pallan
MHMirela Hategan
Mirela Hategan
NPNicola Price
Nicola Price
HAHendrik-Tobias Arkenau
Hendrik-Tobias Arkenau
MWMatthew James Wheater
Matthew James Wheater
E21027Background: Combination BRAF and MEK inhibition in mm has demonstrated improved Overall Survival (OS) and Progression Free Survival (PFS) compared to single agent BRAF inhibition (BRAFi) in phase III testing. Access to the combination in the UK was through a named patient programme for patients with unresectable stage III or IV BRAF mutant melanoma from July 2013. We report on outcome and toxicity data for the cohort. Methods: Retrospective data was collected from casenote and database review of patients treated in 5 UK centers. Physician assessment of response and toxicity was recorded. PFS and OS were calculated from the date of start of treatment to progressive disease or death. Patients still alive or progression free were censored at last clinical review. Results: 73 patients were treated with a median age 55, (range 20 -77). 31 were treatment naïve, 13 had prior immunotherapy. A large proportion (49.3%) received prior BRAFi with Vemurafenib. 20.5% of patients had brain metastases at initiation...

9 June 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
LSLozan Sheriff
Lozan Sheriff
ACAlastair Copland
Alastair Copland
DLDavid A.J. Lecky
David A.J. Lecky
RDReygn Done
Reygn Done
LGLorna S George
Lorna S George
DBDavid Bending
David Bending
Summary: Lag3 and PD-1 are immune checkpoints that regulate T cell responses and are current immunotherapy targets. Yet how they function to control early CD4 + T cell activation remains unclear. Here, we show that the PD-1 and Lag3 pathways exhibit layered control of the early CD4 + T cell activation process, with the effects of Lag3 more pronounced in the presence of PD-1 pathway co-blockade (CB). RNA-sequencing revealed that CB drove an early NFAT-dependent transcriptional profile, including promotion of ICOS hi T follicular helper (Tfh) cell differentiation. NFAT pathway inhibition abolished CB-induced upregulation of NFAT-dependent co-receptors ICOS and OX40, whilst unaffecting the NFAT-independent gene Nr4a1 . Mechanistically, Lag3 and PD-1 pathways functioned additively to regulate the duration of T cell receptor (TCR) signals during CD4 + T cell re-activation. Our data therefore reveal that PD-1 and Lag3 pathways converge to additively regulate TCR signal duration and NFAT-dependent transcriptional activity during early CD4 + T cell re-activation. Highlights: PD-1 and Lag3 pathways exhibit layered control of early CD4 + T cell activation Their co-blockade enhances NFAT-dependent TCR transcriptional programmes Inhibition of NFAT signalling reverses the functional effects of PD-1 and Lag3 co-blockade Mechanistically, PD-1 and Lag3 function to additively regulate TCR signal duration during re-activation of CD4 + T cells

25 August 2026 in The Oncologist
Verified
Journal Article
Open access
MJMagdalene Joseph
Magdalene Joseph
JTJacob Tharakan
Jacob Tharakan
JPJemma Proudfoot-Jones
Jemma Proudfoot-Jones
JSJoseph J Sacco
Joseph J Sacco
AFAndrew JS Furness
Andrew JS Furness
PNPaul Nathan
Paul Nathan
Background: Metastatic uveal melanoma (mUM) carries a poor prognosis, with low response rates to checkpoint inhibitors. The phase III first-line IMCgp100-202 trial established tebentafusp, a bi-specific T cell engager, as the first treatment to demonstrate a survival benefit in mUM. Here, we report retrospective real-world efficacy and toxicity outcomes from the tebentafusp United Kingdom Expanded Access Programme (UK EAP). Patients and methods: 115 HLA-A*02:01 positive patients with mUM were treated between July 2021 and June 2023. 10 of 18 UK EAP centres submitted data, and outcomes for 88 patients are reported here. Data was collected on demographics, disease characteristics, survival, and treatment toxicities and analyzed to identify factors impacting on median overall survival (mOS), median progression-free survival (mPFS), occurrence of cytokine release syndrome (CRS) and grade 3/4 rash. Results: 71% of patients were treated in the first-line setting, with 94% having liver metastases. At a median follow-up of 12 months (range 0 to 34), mOS was 21 months (95% CI, 17 to NR), and mPFS was 2.76 months (95% CI, 2.53-3.22). The 12-month overall survival rate was 75% (95% CI, 66.11-85.6). Lower lactate dehydrogenase (LDH) and lower liver metastatic burden showed a trend towards improved overall survival, with baseline LDH ≥2× ULN conferring a very poor prognosis. Lower liver metastatic burden also associated with reduced frequency of CRS. No ≥ grade 3 toxicity was observed beyond dose 5. Conclusion: Tebentafusp on the UK EAP showed comparable real-world efficacy to the phase III first-line trial data, with manageable toxicities having implications for resource planning.